{
    "clinical_study": {
        "@rank": "100778", 
        "arm_group": [
            {
                "arm_group_label": "Cinepazide, Stroke, Injection", 
                "arm_group_type": "Experimental", 
                "description": "Test drug\uff1aMethanesulfonic acid cinepazide injection\uff085ml/125mg\uff09"
            }, 
            {
                "arm_group_label": "palcebo,Stroke,Injection", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo\uff1asimulation agent of Methanesulfonic acid cinepazide injection\uff085ml sterile water for injection\uff09"
            }
        ], 
        "brief_summary": {
            "textblock": "Using placebo as control, The purpose of this study is to evaluate the efficacy and safety\n      of methanesulfonic acid cinepazide injection to relieve disabled degree of acute cerebral\n      infarction patients, and explore the best safe and effective dose as well as dose method."
        }, 
        "brief_title": "Methanesulfonic Acid Cinepazide Injection for Treatment of Acute Cerebral Infarction", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Ischemic Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Cerebral Infarction", 
                "Stroke", 
                "Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will enroll 288 acute cerebral infarction patients. Patients will be assigned\n      randomly to receive either  Methanesulfonic acid cinepazide injection or placebo treatment.\n      All patient in the study will receive standard of care treatment and clinical, diagnostic,\n      laboratory, safety, and follow-up evaluations. Follow-up evaluations, including National\n      Institute of Health stroke scale(NIHSS), Barthel index score and modified Rankin scale\n      assessments, will be done periodically until 90 days after onset. The degree of disabled\n      improved will be a primary measure of drug effectiveness."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age between 40 and 75 years old\uff0cmale/ female\uff1b\n\n          2. The clinical diagnosis of first onset patients with anterior circulation infarction\n             or who have suffered from stroke in history and complete recover from neurologic\n             impairment (mRS score \uff1c2 before this disease\uff09\n\n          3. Patients is proved by head skull CT and cerebral hemorrhage was excluded\uff1b\n\n          4. course of disease\u226472h\uff0cthe NIHSS score is \u22657 and \u226422\uff1b\n\n          5. Patients who voluntarily  sign written informed consent. -\n\n        Exclusion Criteria:\n\n          1. Patients who suffer from cerebral infarction accompanied by disorder of\n             consciousness, posterior circulation infarction, lacunar infarction and transient\n             ischemic attack.\n\n          2. Patients who suffer from brain arteritis, brain tumor, brain injury, intracranial\n             infection, brain parasitic disease, and so on . Patients who suffer from cardiac\n             diseases such as rheumatic heart disease, coronary heart disease with atrial\n             fibrillation .\n\n          3. Patients who suffer from severe complications, and expected survival period is within\n             three months.\n\n          4. Patients require thrombolysis, anticoagulation, anti- fibrosis treatment .\n\n          5. Patients who suffer from serious brain artery stenosis that should go through\n             interventional therapy .\n\n          6. Patients  whose white blood cells or neutrophils is below the lower limit of the\n             normal reference value .\n\n          7. Patients who have bleeding tendency or suffered from serious bleeding in 3 months.\n\n          8. Patients who have severe cardiac, liver and kidney disease, or whose kidney and liver\n             function tests was abnormal\uff08ALT,AST\u22651.5 times of upper normal limit\uff0cCr\uff1eupper normal\n             limit\uff09.\n\n          9. Patients who have complications of malignant tumor, serious or progressive disease in\n             blood, digestion or other system.\n\n         10. Patients who have complications of mental illness un can not or do not want willing\n             to cooperate .\n\n         11. Doubt or does have alcohol, drug abuse history\n\n         12. Allergic constitution or allergic to the test drug ingredients .\n\n         13. Pregnancy and lactation women or those who has a recent fertility plan\n\n         14. Patients who have participated in other clinical experiments three months before this\n             test.\n\n         15. The patients who is unsuitable to participate in the clinical test in the view of\n             researchers"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "288", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01851759", 
            "org_study_id": "xijing005"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cinepazide, Stroke, Injection", 
                "description": "2 branches of Methanesulfonic acid cinepazide injection  were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.\n1 branch of simulation agent of Methanesulfonic acid cinepazide injection was matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.", 
                "intervention_name": "cinepazide", 
                "intervention_type": "Drug", 
                "other_name": "Methanesulfonic acid cinepazide injection"
            }, 
            {
                "arm_group_label": "palcebo,Stroke,Injection", 
                "description": "2 branches of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.\n1 branch of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug", 
                "other_name": "simulation agent of Methanesulfonic acid cinepazide"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 7, 2013", 
        "location": {
            "contact": {
                "email": "zhaogang@fmmu.edu.cn", 
                "last_name": "Gang Zhao", 
                "phone": "02984775361"
            }, 
            "facility": {
                "address": {
                    "city": "Xi'an", 
                    "country": "China", 
                    "state": "Shaanxi", 
                    "zip": "710032"
                }, 
                "name": "Xijing Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Random, Double-blind, Placebo- Controlled and Dose-finding, Multi-center, Phase II Clinical Trial of Methanesulfonic Acid Cinepazide Injection for Treatment of Acute Cerebral Infarction", 
        "overall_contact": {
            "email": "zhaogang@fmmu.edu.cn", 
            "last_name": "Gang Zhao, Doctor"
        }, 
        "overall_official": {
            "affiliation": "Xijing Hospital", 
            "last_name": "Gang Zhao, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "modified Rankin scale", 
            "safety_issue": "No", 
            "time_frame": "3 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01851759"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Barthel index", 
            "safety_issue": "No", 
            "time_frame": "3 month"
        }, 
        "source": "Xijing Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xijing Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}